Intuitive Surgical, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +15

How Far Could ISRG Stock Bounce From Here?

AI-generated analysis

📈 ISRG stock faces a potential 23.9% upside rally to $487.45 if it clears technical resistance at $429.72 and $452.35.

⚠️ Historical data shows that over the last two years, every time ISRG entered this price range, it failed to generate a 20% gain before dropping 5%.

📉 US da Vinci procedure growth slowed to 12% in Q2 2026 from 14% in Q1, driven by patients delaying elective care due to insurance coverage changes.

💰 ISRG placed 468 da Vinci systems in the second quarter of 2026, representing an 18% increase compared to the same period last year.

📊 Revenue grew 20.7% over the last twelve months, significantly exceeding the S&P 500 median growth rate of 8.3%.

💸 An extended use program introduced in H1 2027 allows instruments to be used more times, potentially lowering the price per procedure for benign surgeries.

📉 The stock trades at 44.4 times earnings, a premium valuation that is vulnerable if lower pricing per procedure materializes.

🔍 Management expects deferred medical conditions will eventually progress and require treatment, supporting long-term demand despite current delays.

Bullish Signals
  • ISRG placed 468 da Vinci systems in Q2 2026, an 18% year-over-year increase in hospital placements.
  • Revenue grew 20.7% over the last twelve months, significantly outpacing the S&P 500 median of 8.3%.
  • The shift toward da Vinci 5 systems has been accretive to revenue per procedure.
Risk Factors
  • US da Vinci procedure growth slowed to 12% in Q2 2026 from 14% in Q1, indicating a slowdown in elective procedures.
  • Customers report that insurance coverage changes are affecting when patients seek care for treatable conditions.
  • An extended use program starting in H1 2027 may lower the price per procedure for benign surgeries, potentially denting margins.
  • The stock trades at 44.4 times earnings, a valuation more than double the S&P 500 median of 22.4x, making it sensitive to growth disappointments.
Full Analysis
Intuitive Surgical (ISRG) stock is currently trading at $393.33, presenting a technical setup where buyers could see a potential 23.9% rally to the April high of $487.45, though historical price action over the last two years suggests caution as no prior entry in this range resulted in a 20% gain before a 5% drop. Fundamental concerns weigh on the stock, specifically a slowdown in US da Vinci procedure growth which decelerated to 12% in the second quarter of 2026 from 14% in the first. Management attributes this partly to patients delaying elective procedures due to coverage changes and the law of large numbers, while competitors' pricing strategies via extended use programs threaten to lower revenue per procedure. Despite these headwinds, ISRG maintains strong operational momentum with hospitals continuing to purchase systems; the company placed 468 da Vinci units in Q2 2026, an 18% increase year-over-year. Revenue growth remains robust at 20.7% over the last twelve months, significantly outpacing the S&P 500 median of 8.3%, though the stock trades at a premium valuation of 44.4 times earnings compared to the index median of 22.4.